Clinical Trials Browser

Phase 2 × OTHER_GOV × ibrutinib × Clear all

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse